Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) finished Thursday with a subtraction of -$0.07 to close at $0.57, a downside of -11.12 percent. An average of 3,766,460 shares of common stock have been traded in the last five days. There was a fall of -$0.2919 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 3,165,190 shares traded, while the 50-day average volume stands at 8,292,362.
TNXP stock has decreased by -54.85% in the last month. The company shares reached their 1-month lowest point of $0.5625 on 09/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.62 and a high of $20.32 in 52 weeks. It has reached a new high 2 times so far this year and lost -95.03% or -$10.8775 in price. In spite of this, the price is down -97.20% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
Tonix Pharmaceuticals Holding Corp. (TNXP) stock’s beta is 1.61. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.05.
The quick ratio of Tonix Pharmaceuticals Holding Corp. for the three months ended March 30 was 12.10, and the current ratio was 12.10, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Tonix Pharmaceuticals Holding Corp.’s return on assets was -42.70%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$27.4 million in the quarter, while revenues of -$26.42 million were grew 14.05%. The analyst consensus anticipated Tonix Pharmaceuticals Holding Corp.’s latest quarter earnings to come in at -$1.49 per share, but it turned out to be -$1.6, a -7.40% surprise. For the quarter, EBITDA amounted to -$23.23 million. Shareholders own equity worth $43.06 million.
From a technical analysis perspective, let’s take a brief look at Tonix Pharmaceuticals Holding Corp. (TNXP) price momentum. RSI 9-day as of the close on 22 September was 13.69%, suggesting the stock is oversold, with historical volatility in this time frame at 12.08%.
As of today, TNXP’s price is $0.6709 -33.91% or -$0.2919 from its 5-day moving average. TNXP is currently trading -55.90% lower than its 20-day SMA and -87.81% lower than its 100-day SMA. However, the stock’s current price level is -57.86% below the SMA50 and -95.66% below the SMA200.
The stochastic %K and %D were 1.94% and 2.36%, respectively, and the average true range (ATR) was 0.0801. With the 14-day stochastic at 1.26% and the average true range at 0.0959, the RSI (14) stands at 21.43%. The stock has reached -0.1577 on the 9-day MACD Oscillator while the 14-day reading was at -0.2260.
Noble Capital Markets launched coverage on Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) in its analyst report released on April 18, 2022. The firm assigned the stock an Outperform rating. The consensus rating for Tonix Pharmaceuticals Holding Corp. (TNXP) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TNXP, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is TNXP’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $10.00, with a median target of $10.00. Taking a look at these predictions, the average price target given by analysts for Tonix Pharmaceuticals Holding Corp. (TNXP) stock is $10.00.